Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back
Evaluation ViewAttendees 77
Debate/Pro-Con Discussion

Academic and Research Skills

Critical Care

Hospital Medicine

Infectious Diseases

Neonatology

Trainee
Session Type: Debate/Pro-Con Discussion

Clashes Over Sepsis: Debating Infectious Diseases in the ICU

Friday, May 3, 2024
3:45 PM – 5:15 PM ET
Location: Metro Toronto Convention Centre: 205
CE: Live CME: 1.5

Selected By: CC
Co-sponsored By: PIDS
Disclosure(s):
Joshua Wolf, MBBS, PhD: Karius Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Merck Inc (Terminated, September 1, 2023) (Products/Services: Research Support including clinical trials & the principal or named investigator); Pfizer Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)

Session

Description: Targeted at intensivists and subspecialist or generalist pediatricians, these 3 rapidfire debates will address current controversies in prevention, diagnosis and management of infections in the PICU. The focus is on practical and applicable analysis of available data, and attempting to provide some consensus at the end! They will feature established and rising stars in the world of Infectious Diseases,

The topics are: 1. That antibiotics should be routinely discontinued after 2 days in children with culture-negative severe sepsis; 2. That infectious diseases consultation should be required for all children with severe sepsis; and 3. That all infants in neonatal intensive care units should undergo regular screening for colonization with multi-drug resistant bacteria.

Learning Objectives:

  • Synthesize data about role of short vs. long empiric therapy for culture negative sepsis in the PICU.
  • Describe the role of routine infectious diseases consultation in children with severe sepsis in the PICU.
  • Understand the potential risks and benefits of routine screening for multidrug resistant organisms in the NICU.

Presentations:

  • 3:45 PM – 3:58 PM ET
    That antibiotics should be routinely discontinued after 2 days in children with culture-negative severe sepsis - Pro

    Speaker: Sandra R. Arnold, MD, MSc (she/her/hers) – University of Tennessee Health Science Center

  • 3:58 PM – 4:11 PM ET
    That antibiotics should be routinely discontinued after 2 days in children with culture-negative severe sepsis - Con

    Speaker: Madhuradhar Chegondi, MD (he/him/his) – University of Iowa Stead Family Children's Hospital

  • 4:11 PM – 4:24 PM ET
    That infectious diseases consultation should be required for all children with severe sepsis - Pro

    Speaker: Erica C. Prochaska, MD (she/her/hers) – Johns Hopkins University School of Medicine

  • 4:24 PM – 4:37 PM ET
    That infectious diseases consultation should be required for all children with severe sepsis - Con

    Speaker: Julie Fitzgerald, MD PhD MSCE – University of Pennsylvania, Children's Hospital of Philadelphia

  • 4:37 PM – 4:50 PM ET
    That all infants in NICUs should undergo regular screening for colonization with multi-drug resistant bacteria - Pro

    Speaker: Nick Hysmith, MD, MS, MBA – University of Tennessee Health Science Center College of Medicine

  • 4:50 PM – 5:03 PM ET
    That all infants in NICUs should undergo regular screening for colonization with multi-drug resistant bacteria - Con

    Speaker: Thomas J. Sandora, MD MPH – Division of Infectious Diseases, Boston Children's Hospital